Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

928 - Molecular Tumor Board (MTB): development of clinical pathways for precision medicine. Experiences of Center for Breast cancer at National cancer center, Korea


24 Nov 2018


Poster display - Cocktail


Targeted Therapy

Tumour Site

Breast Cancer


In Hae Park


Annals of Oncology (2018) 29 (suppl_9): ix13-ix20. 10.1093/annonc/mdy428


I.H. Park1, C. Park2, W. Jang1, H. Yang1, K. An1, Y. Kwon3, K.S. Lee4, S.H. Sim1, S.Y. Kong1

Author affiliations

  • 1 Research Institute, National Cancer Center, 10408 - Gyeonggi-do/KR
  • 2 Research Institute, National cancer center, Goyang/KR
  • 3 Center For Breast Cancer, National Cancer Center, 10408 - Gyeonggi-do/KR
  • 4 Research Institute And Hospital, National Cancer Center, Goyang/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 928


Many of the newly approved drugs in breast cancer are not based on just conventional subtypes but are targeting to a variety of cancer characteristics, such as DNA repair, metabolism, apoptosis, or immune. NGS-based biomarker research is particularly needed in triple-negative breast cancer (TNBC) with no effective treatment. Collaborative research among researchers based on genetic information from patients can further improve patient care. Purpose of this project was the development of Clinical pathways for Realization of Customized Therapy and Building the Platform for Practical Application.


Patients with metastatic TNBC were enrolled and reviewed in the MTB with clinical records and comprehensive next gene sequencing (NGS) data including wholes exome sequencing and RNA sequencing. MTB was consisted with medical oncologists, pathologists, bioinformaticians, and geneticists. The variants of the genes in NGS testing were classified into 3 categories in the order of 1 to 3 based on data quality and clinical meanings.


A total of 48 cases were submitted to the MTB. The median age was 50 (range 36-69). 64.6% of patients have not been treated for their metastatic TNBC. TP53, PI3KCA and KDM6A were most frequent variants in these patient population. In each patient, median 2 genetic variants (level 1 and 2) were detected like PI3KCA, ERBB2, AKT, BRCA1 and BRAF etc. We also found a case having FGFR2-RASSF3 fusion which was potential targetable variant. For CNV analysis, CCND1 (11q13.3), MYC (8q24.21), and NOTCH3 (1q21.3) were found to be amplified and those cases were considered as candidates for targeted therapy.


Identification of a driver, targetable genetic mutation can lead to a specific targeted therapy and result in personalized therapy. NGS is a powerful tool to detect candidate targets, however better understanding and timely incorporation in clinical care are needed. MTB has a role to serve a forum to educate attendee from various clinical and research fields and to play a center point to proceed precision medicine.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

National Cancer Center, Goyang, Korea.


National Cancer Center, Goyang, Korea.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.